NAGE NASDAQ
Niagen Bioscience Inc
1W: -8.5%
1M: -12.0%
3M: -20.3%
YTD: -55.4%
1Y: -64.6%
3Y: +92.4%
5Y: -56.7%
$2.79
+0.11 (+4.10%)
Weekly Expected Move ±5.5%
$2
$3
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
18 relationships18
As Filer
counterparties named
0
As Counterparty
mentioned by others
7
Rel. Types
2022-05-19
Earliest Filing
2025-12-22
Latest Filing
partner: 8
investor: 3
JV: 3
acquirer: 1
target: 1
customer: 1
supplier: 1
Counterparties (Filed by NAGE)
18 relationshipsCompanies named in NAGE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| ChromaDex, Inc. | NAGE | acquirer | Acquired patent rights from Queen's University Belfast via assignment agreement. | 2025-12-22 | View |
| Queen's University Belfast | — | target | Assigned patent rights to ChromaDex, Inc. and received payment for release of prior obligations. | 2025-12-22 | View |
| ChromaDex, Inc. | NAGE | customer | Wholly owned subsidiary of Niagen Bioscience, Inc. that entered into a supply agreement to purchase NRCL. | 2025-07-29 | View |
| W. R. Grace & Co.-Conn | — | supplier | Exclusively supplies Nicotinamide-beta-Riboside Chloride (NRCL) to ChromaDex, Inc. | 2025-07-29 | View |
| Roth Capital Partners | — | partner | Added as a Sales Agent under the At Market Issuance Sales Agreement | 2024-11-21 | View |
| Raymond James & Associates | — | partner | Continued as a Sales Agent under the At Market Issuance Sales Agreement | 2024-11-21 | View |
| Asia Pacific Scientific, Inc. | — | partner | Indirect subsidiary of ChromaDex that entered into a shareholders agreement with Taikuk to form a joint venture. | 2022-10-03 | View |
| Hong Kong Taikuk (China) Group Ltd | — | partner | Company that agreed to contribute $1.0 million for an 11% non-voting equity interest in the joint venture. | 2022-10-03 | View |
| Pioneer Step Holdings Limited | — | investor | Existing stockholder that purchased $1.25 million of ChromaDex common stock in a securities purchase agreement. | 2022-10-03 | View |
| Champion River Ventures Limited | — | investor | Existing stockholder that purchased $1.25 million of ChromaDex common stock in a securities purchase agreement. | 2022-10-03 | View |
| Robert Fried | — | investor | Board member and CEO who purchased $625,000 of ChromaDex common stock in a securities purchase agreement. | 2022-10-03 | View |
| Crystal Lake Developments Limited | — | partner | Affiliate of Champion River that was a party to a terminated joint venture agreement. | 2022-10-03 | View |
| Pioneer Idea Holdings Limited | — | partner | Affiliate of Pioneer Step that was a party to a terminated joint venture agreement. | 2022-10-03 | View |
| China National Pharmaceutical Group Co., Ltd. | — | partner | Company whose distribution agreements are being assigned to the joint venture for product commercialization. | 2022-10-03 | View |
| Crystal Lake Developments Limited | — | JV | Joint venture partner contributing $1.8 million to commercialize Tru Niagen in Mainland China | 2022-05-19 | View |
| Pioneer Idea Holdings Limited | — | JV | Joint venture partner contributing $1.2 million to commercialize Tru Niagen in Mainland China | 2022-05-19 | View |
| Hong Kong Taikuk (China) Group Ltd | — | JV | Joint venture partner contributing $1.0 million and receiving 5% non-voting equity interest | 2022-05-19 | View |
| China National Pharmaceutical Group Co., Ltd | — | partner | Distribution partner for commercializing Products in the Territory via cross-border platform | 2022-05-19 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-04 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-06-29 | Shareholder Vote | View | |
| 2026-03-04 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-02-26 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-12-22 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-11-06 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-04 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-10-06 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-06 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-07-29 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-06-27 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-07 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-03-19 | Amendments to Articles of Incorporation or Bylaws; Regulation FD Disclosure; Financial Statements an | View | |
| 2025-03-04 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-02-27 | Departure/Election of Directors; Appointment of Officers | View | |
| 2024-12-16 | Changes in Registrant's Certifying Accountant | View | |
| 2024-12-04 | Other Events | View | |
| 2024-11-21 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2024-10-31 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2024-10-11 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR